View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 26, 2011

New Breath Test to Diagnose Chronic Pancreatitis

Exalenz Bioscience has announced positive trial data that reveals its BreathID breath test system and 13C-di-peptide substrate could be used to diagnose chronic pancreatitis. The study, which included 33 subjects, compared the accuracy of the 13C-di-peptide breath test to the endoscopi

By cms admin

Exalenz Bioscience has announced positive trial data that reveals its BreathID breath test system and 13C-di-peptide substrate could be used to diagnose chronic pancreatitis.

The study, which included 33 subjects, compared the accuracy of the 13C-di-peptide breath test to the endoscopic pancreatic function test, and also measured the ability of the breath test to differentiate between healthy subjects and those with chronic pancreatitis.

The findings from the study concluded that a 13C-di-peptide breath test using the BreathID system can non-invasively diagnose chronic pancreatitis with good accuracy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management